Jamjoom Pharma’s Financial Results in Q1/2026 1Q 2026 Financial Summary SAR (mn) 1Q 2026 1Q 2025 YOY Δ% Revenue 481.4 457.5 +5% Gross profit 310.4 292.8 +6% Operating profit 172.4 158.2 +9% Net profit 168.2 157.0 +7% EBITDA 186.7 172.4 +8% FCF 180.5 156.6 +15% EPS 2.4 2.2 +7% JEDDAH, 23rd April 2026 –…
Manufacturing agreement announced between Jamjoom Pharma and Viatris Arabia Limited LLC Saudi Arabia – [22-04-2026] – Jamjoom Pharma, a leading Saudi pharmaceutical healthcare company in the Middle East and Africa (MEA), and Viatris Arabia Limited “LLC”, a part of global healthcare company Viatris, announced a local manufacturing agreement by which Jamjoom Pharma will manufacture several…
“Jamjoom Pharma” and “Caritas Egypt” launch a strategic partnership to enhance eye health and support presidential health initiatives Cairo, 21 April 2026: Jamjoom Pharma, one of the fastest-growing pharmaceutical companies in Saudi Arabia and across MEA, announced the signing of a memorandum of understanding with Caritas Egypt, aimed at launching a comprehensive national initiative for…
